(Bandar Seri Begawan, 14th) JPMC on the 13th of this month ceremoniously announced the official launch of Nucleic Acid Amplification Testing (NAAT) at Jerudong Park Medical Centre.
This launch marks an important step forward for Brunei in strengthening laboratory diagnostic capabilities and improving blood safety standards.
JPMC board member Hajah Dewi Sarwani attended this grand event as the guest of honor. The ceremony began with the recitation of Surah Al-Fatihah (the Opening) from the Quran and a prayer (Doa Selamat), followed by a demonstration of the brand-new NAAT system.
Nucleic Acid Amplification Testing (NAAT) utilizes the cobas® 5800 system, which is an advanced testing method capable of directly detecting viral genetic material (RNA/DNA) in blood samples from donors.
In addition to traditional antibody- and antigen-based screening, NAAT can identify infections at a much earlier stage—even before the human body produces detectable antibodies or antigens.
By enabling early detection, this technology increases the safety of blood transfusions and reduces the risk of undiagnosed infections. It also improves screening sensitivity, thereby allowing for more reliable identification of viruses such as HIV and hepatitis, ensuring patients receive safer therapeutic outcomes.
JPMC Laboratory Manager and Consultant Dr. Mohamad stated that this is about safer blood for every patient. NAAT allows us to detect infections earlier and comprehensively reduce risk.
The introduction of NAAT enhances the diagnostic capabilities of JPMC, enabling more accurate and timely testing, while also complementing existing screening methods and aligning with international best practices.
This advancement contributes to a safer transfusion process and reinforces JPMC’s commitment to providing high-quality, patient-centered medical services.
The JPMC senior management team, healthcare professionals, and key stakeholders attended the event, demonstrating a shared commitment to improving diagnostic standards and patient safety.
This launch marks an important step forward for Brunei in strengthening laboratory diagnostic capabilities and improving blood safety standards.
JPMC board member Hajah Dewi Sarwani attended this grand event as the guest of honor. The ceremony began with the recitation of Surah Al-Fatihah (the Opening) from the Quran and a prayer (Doa Selamat), followed by a demonstration of the brand-new NAAT system.
Nucleic Acid Amplification Testing (NAAT) utilizes the cobas® 5800 system, which is an advanced testing method capable of directly detecting viral genetic material (RNA/DNA) in blood samples from donors.
By enabling early detection, this technology increases the safety of blood transfusions and reduces the risk of undiagnosed infections. It also improves screening sensitivity, thereby allowing for more reliable identification of viruses such as HIV and hepatitis, ensuring patients receive safer therapeutic outcomes.
JPMC Laboratory Manager and Consultant Dr. Mohamad stated that this is about safer blood for every patient. NAAT allows us to detect infections earlier and comprehensively reduce risk.
The introduction of NAAT enhances the diagnostic capabilities of JPMC, enabling more accurate and timely testing, while also complementing existing screening methods and aligning with international best practices.
This advancement contributes to a safer transfusion process and reinforces JPMC’s commitment to providing high-quality, patient-centered medical services.
The JPMC senior management team, healthcare professionals, and key stakeholders attended the event, demonstrating a shared commitment to improving diagnostic standards and patient safety.